TTR and cardiomyopathy: Patients with ATTR-CM or ATTRv amyloidosis due to the p.V142I (ATTRV122I) TTR mutation or other TTR variant cardiomyopathies will likely be significantly affected by COVID-19, perhaps disproportionately so.